dinutuximab
Sign in to saveAlso known as Ch14.18, ch14.18-UTC
Dinutuximab (Ch14.18, tradename Unituxin) and dinutuximab beta (tradename Qarziba) are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab beta is manufactured using hamster cells. The dosing regime differs, and dinutuximab is given in combination
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- xi/o
- Drug.target
- GD2
- Drug.tradename
- Unituxin, Qarziba, others
- Drug.MedlinePlus
- a615022
- Drug.DailyMedID
- Dinutuximab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FX06
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1363687-32-4
via Wikipedia infobox
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2015
- Admin. routes
- parenteral
- Indications
- neuroblastoma, neoplasm, osteosarcoma, small cell lung carcinoma
via ChEMBL · EBI
Research
310 papers- Dinutuximab.2006
- Dinutuximab.2012
- Dinutuximab beta for neuroblastoma.Australian prescriber · 2020
- Safety and efficacy of dinutuximab in the treatment of neuroblastoma: A review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023
- Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 3 more facts
- World Health Organisation international non-proprietary name
- dinutuximab
- subject has role
- monoclonal antibody
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~7 min read
Encyclopedic overview
6 sectionsContents
- Medical use
- Adverse effects
- Pharmacology
- Chemistry
- History
- References
Dinutuximab (Ch14.18, tradename Unituxin) and dinutuximab beta (tradename Qarziba) are monoclonal antibodies used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab beta is manufactured using hamster cells. The dosing regime differs, and dinutuximab is given in combination with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), while dinutuximab beta can be given alone.
They both cause severe side effects, including severe pain that must be controlled with morphine, and a high risk of infusion reaction that must be controlled with antihistamines and anti-inflammatory drugs. They both work by binding to neurons and causing the body's immune system to destroy them.
Excerpted from Wikipedia’s “dinutuximab” article, available under the CC BY-SA 4.0 licence.